Asthma-COPD overlap (ACO)
mixed obstruction · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
ACO describes persistent airflow limitation with features of both asthma (variability, eosinophilia, atopy) and COPD (smoking/exposure, incomplete reversibility). It is a pragmatic label, not a single disease, and carries higher exacerbation and symptom burden than either alone.
Red flags
- Frequent exacerbations despite triple therapy
- Rapid FEV1 decline
- Hypoxaemia / cor pulmonale
- Weight loss or haemoptysis prompting malignancy work-up
Assessment
Differential diagnosis
- Asthma with fixed airflow obstruction
- COPD with eosinophilia/bronchodilator reversibility
- Bronchiectasis
- Chronic heart failure
- Combined pulmonary fibrosis and emphysema
Investigations
- Post-bronchodilator spirometry (FEV1/FVC <0.70 with significant reversibility)
- Blood eosinophil count
- FeNO
- Total/specific IgE and atopy assessment
- Chest X-ray / HRCT to assess emphysema and exclude bronchiectasis
- Lung volumes and DLCO; alpha-1 antitrypsin if emphysema and limited smoking
Management
- Confirm persistent airflow obstruction with incomplete reversibility
- Document both asthma (variability, eosinophils, atopy) and COPD (smoking/biomass, structural damage) features
- Quantify exacerbation history and symptom burden (CAT/mMRC)
- Start ICS-containing therapy early (never LABA or LAMA alone) because of the asthma component
- Build to triple therapy ICS-LABA-LAMA where symptoms/exacerbations persist
- Address smoking cessation aggressively and ensure vaccinations
- Assess eosinophils to guide ICS intensity and exacerbation risk
- Enrol in pulmonary rehabilitation
- Treat comorbidities and manage exacerbations as for the dominant phenotype
- Review response and consider specialist phenotyping if poorly controlled
Drugs & doses
ICS-LABA e.g. budesonide-formoterol 200/6 mcg 2 puffs twice daily
Triple therapy e.g. fluticasone furoate-umeclidinium-vilanterol 92/55/22 mcg once daily
Tiotropium 2.5 mcg 2 puffs once daily (LAMA)
Varenicline 1 mg PO twice daily for smoking cessation
Disposition
General respiratory clinic; pulmonary rehab referral; specialist review if refractory.
Complications & pitfalls
- Accelerated lung-function decline
- Frequent exacerbations and hospitalisation
- Pneumonia risk from inhaled steroids
- Progression to chronic respiratory failure
Exam pearls
- Never treat the airflow obstruction as pure COPD with bronchodilator-only therapy if asthma features exist — ICS is key
- Higher eosinophils predict ICS responsiveness and exacerbation risk
- ACO patients have worse quality of life than asthma or COPD alone
- Always exclude bronchiectasis and heart failure as contributors
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.